Investor Overview

Stock Information
Loading data...

Shares outstanding

121.2 million (as of 12/16/2022)

Press Releases
Mar 21, 2023

– Company cuts management pay and lowers headcount to decrease operating costs – – Reductions align with corporate goal to reach cash flow break even by year-end 2023 – SAN DIEGO, March...

Mar 9, 2023

Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to...

Feb 28, 2023

-- Phexxi is the first and only hormone-free contraceptive offered by reproductive telehealth leader SimpleHealth to its patients -- SAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Evofem Biosciences,...

Feb 27, 2023

-- Evofem now has four Orange Book listed patents covering Phexxi into 2033 -- SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that two additional...

Feb 23, 2023

Evofem Biosciences, Inc. (OTCQB: EVFM), announced today that its Board of Directors has unanimously approved a comprehensive strategic process to explore and evaluate strategic alternatives to...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The U.S. contraceptive market was estimated at $7.9 billion as of 2021. Every 1% market share of the 42.2 million women in our addressable market represents more than $300 million in net product sales for Evofem.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". 

Featured Event
Tuesday, October 25, 2022
11:35 am PDT

"Pregnancies by Acts of Intercourse with Vaginal pH Modulator: Results from the AMPOWER Study," was given as an oral presentation during the ASRM 2022 Scientific Congress.

View All

Latest Financial Results

Q2 2022, Ended June 30th, 2022

Earnings Release
Earnings Call
10-Q Filing